SymptomsBy Mayo Clinic staff
Sometimes, there may be no noticeable signs or symptoms from prolactinoma. When signs and symptoms are present, they may be caused by excessive prolactin in your blood (hyperprolactinemia) or, if the tumor is large, from the pressure of the tumor on surrounding tissues. Because elevated levels of the hormone prolactin cause disruption of the reproductive system (hypogonadism), some of the signs and symptoms of prolactinoma are specific to females or males.
- Irregular menstrual periods (oligomenorrhea) or lack of menstrual periods (amenorrhea)
- Milky discharge from the breasts (galactorrhea) when not pregnant or breast-feeding
- Painful intercourse due to vaginal dryness
- Acne and excessive body and facial hair growth (hirsutism)
- Erectile dysfunction (ED)
- Uncommonly, enlarged breasts (gynecomastia)
In both sexes
- Low bone density
- Reduced other hormone production by the pituitary gland (hypopituitarism) as a result of tumor pressure
- Loss of interest in sexual activity
- Visual disturbances
Women tend to notice signs and symptoms earlier than men do, when tumors are smaller in size, probably because they're alerted by missed or irregular menstrual periods. Men, on the other hand, tend to notice signs and symptoms later, when tumors are much larger and more likely to cause headache or vision problems.
When to see a doctor
If you develop signs and symptoms associated with prolactinoma, see your doctor to determine the cause.
- Prolactinoma. National Institute of Diabetes and Digestive and Kidney Diseases. http://endocrine.niddk.nih.gov/pubs/prolact/prolact.htm. Accessed Jan. 17, 2011.
- Melmed S, et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2011;96:273.
- Colao A, et al. Therapy of aggressive pituitary tumors. Expert Opinion Pharmacotherapy. 2011;12:1561.
- Mann WA. Treatment for prolactinomas and hyperprolactinaemia: A lifetime approach. European Journal of Clinical Investigation. 2011;41:334.
- Klibanski A. Prolactinomas. The New England Journal of Medicine. 2010;352:121.
- Colao A, et al. Medical treatment of prolactinomas. Nature Reviews Endocrinology. 2011;7:267.
- Parlodel (prescribing information). East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012. http://www.pharma.us.novartis.com/product/pi/pdf/parlodel.pdf. Accessed Nov. 13, 2012.
- Cycloset (prescribing information). San Diego, Calif.: VeroScience, LLC; 2010. http://www.veroscience.com/CyclosetFDAapprovedPackageInsert.htm. Accessed Nov. 13, 2012.
- Cabergoline (prescribing information). Sellersville, Pa.: Teva Pharmaceuticals; 2012. http://www.tevagenerics.com/default.aspx?pageid=3364&sortby=ProductName&ProductName=Cabergoline+Tablets&BrandName=Dostinex%C2%AE+Tablets. Accessed Nov. 13, 2012.
- Martinkova J, et al. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clinical Neuropharmacology. 2011;34:179.